Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide

  title={Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide},
  author={Frida Loria and Stefania Petrosino and Leyre Mestre and Alessandra Spagnolo and Fernando G Correa and M{\'i}riam Hernang{\'o}mez and Carmen Guaza and Vincenzo Di Marzo and Fabian Docagne},
  journal={European Journal of Neuroscience},
Cannabinoids have recently been approved as a treatment for pain in multiple sclerosis (MS). Increasing evidence from animal studies suggests that this class of compounds could also prove efficient to fight neurodegeneration, demyelination, inflammation and autoimmune processes occurring in this pathology. However, the use of cannabinoids is limited by their psychoactive effects. In this context, potentiation of the endogenous cannabinoid signalling could represent a substitute to the use of… 
Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease
It is proposed that the peripheral CB1 receptor is involved in the regulation and amelioration of inflammation associated with autoimmune diseases.
The endocannabinoid system and its therapeutic exploitation in multiple sclerosis : Clues for other neuroin fl ammatory diseases
The preclinical and clinical studies that could explain the therapeutic action of cannabinoid-based medicines, as well as the medical potential of modulating endocannabinoid signaling in multiple sclerosis, with a link to other neuroinflammatory disorders that share common hallmarks and pathogenetic features are reviewed.
The endocannabinoid system: a revolving plate in neuro-immune interaction in health and disease
Current information on immune effects of cannabinoids in health and disease is outlined and it is shown that the endocannabinoid system represents a revolving plate of neural and immune interactions.
Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review
This mini review article summarizes what is currently known about the peripheral and central effects of cannabinoids in relation to the neuroinflammation coupled to MS, with special attention to their effects on remyelination and axon preservation within the CNS.
Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders
Its non-psychoactive effect makes theCB2R a potential target for treating CNS disorders; however, a better understanding of the fundamental pharmacology of CB2R activation is essential for the design of novel therapeutic strategies.


Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosis
The results indicate that treatment during established disease significantly improves the motor function of the diseased mice and suggest that agents able to activate the endocannabinoid system could constitute a new series of drugs for the treatment of MS.
Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis
OMDM1 and OMDM2 provide an effective therapy for Theiler murine encephalomyelitis virus‐induced demyelinating disease (TMEV‐IDD) and point to the manipulation of the endocannabinoid system as a possible strategy to develop future MS therapeutic drugs.
The (endo)cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis.
Cannabinoid CB1 and CB2 Receptors and Fatty Acid Amide Hydrolase Are Specific Markers of Plaque Cell Subtypes in Human Multiple Sclerosis
As seen for other neuroinflammatory conditions, selective glial expression of cannabinoid CB1 and CB2 receptors and FAAH enzyme is induced in MS, thus supporting a role for the endocannabinoid system in the pathogenesis and/or evolution of this disease.
The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis.
Evidence for a new site of CB(2) receptor action, namely the targeting of myeloid progenitor trafficking and its contribution to microglial activation, is provided and the potential use of non-psychoactive CB( 2) agonists in therapeutic strategies for multiple sclerosis and other neuroinflammatory disorders is supported.
Drug Insight: effects mediated by peroxisome proliferator-activated receptor-γ in CNS disorders
The finding that activation of peroxisome proliferator-activated receptor-γ (PPARγ) suppresses inflammation in peripheral macrophages and in models of human autoimmune disease instigated the